Direct Cost Analysis: Wegovy vs Mounjaro Pricing
Understanding the Cost of Wegovy vs Mounjaro Mechanisms
The cost of Wegovy reflects its sophisticated semaglutide formulation, a GLP-1 receptor agonist that mimics natural fullness hormones. This prescription-only medicine works by reducing appetite and promoting satiety after smaller meals, potentially reducing food cravings through direct action on brain appetite centres. Mounjaro utilises tirzepatide, a dual GIP and GLP-1 receptor agonist, offering a different mechanism that targets two hormone pathways simultaneously. This dual-action approach creates distinct cost considerations, as tirzepatide represents newer pharmaceutical technology.
When evaluating the cost of Wegovy versus Mounjaro, consider that Wegovy follows a five-dose escalation protocol (0.25mg to 2.4mg) whilst Mounjaro progresses through six doses (2.5mg to 15mg). The dosing differences directly impact monthly costs, as each medication requires different quantities and concentrations. Wegovy's established clinical profile, demonstrated in the comprehensive STEP trial programme, supports its pricing structure. Both medications require prescription oversight and clinical monitoring, contributing to the overall treatment investment beyond the medication cost itself.
Wegovy Cost Breakdown: Transparent Pricing Structure
The cost of Wegovy at EverydayMeds follows a clear escalation pricing model aligned with the mandatory dose increases. Starting doses cost £79.99 for 0.25mg (weeks 1-4), progressing to £94.99 for 0.5mg (weeks 5-8), then £99.99 for 1mg (weeks 9-12). The therapeutic doses continue with £139.99 for 1.7mg (weeks 13-16), reaching the maintenance dose of 2.4mg at £209.99 from week 17 onwards. Our bundle options provide convenient multi-dose packages: the Intro Trio containing 0.25mg, 0.5mg, and 1mg doses costs £299.99, covering your first 12 weeks of treatment.
Discount codes significantly impact the final cost of Wegovy, with FIRST40 for new customers and DOSE25 for returning patients applied at checkout to reach these competitive prices. The Ultimate Stability Trio offers three months of maintenance 2.4mg supply for £649.99, providing treatment continuity. Bundle pricing emphasises convenience and Reliable Supply rather than pure cost savings, ensuring uninterrupted access to your prescribed medication. Monthly maintenance costs stabilise at £209.99 once you reach the 2.4mg therapeutic dose, making long-term budgeting straightforward.
Clinical Evidence Supporting Wegovy Cost Effectiveness
The cost of Wegovy reflects substantial clinical validation through the comprehensive STEP trial programme. In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo, as reported by Wilding et al., NEJM, 2021. The STEP 5 extension demonstrated sustained clinically studied weight loss maintained over two years, supporting the long-term value proposition.
Recent SELECT cardiovascular outcomes data showed 20% reduction in major cardiovascular events (HR 0.80), potentially offsetting medication costs through reduced healthcare utilisation. These clinical outcomes may justify the cost of Wegovy for patients with cardiovascular risk factors, though individual results will vary and depend on adherence to prescribed lifestyle modifications alongside medication therapy.
How Wegovy Works: Mechanism Justifying Cost
Wegovy contains semaglutide, a GLP-1 receptor agonist that replicates the action of natural incretin hormones released after eating. The medication binds to GLP-1 receptors in the brain, stomach, and pancreas, creating multiple physiological effects that support weight management. In the stomach, Wegovy slows gastric emptying, extending feelings of fullness after meals and reducing the desire to eat frequently. The brain-based effects include direct action on appetite control centres in the hypothalamus, potentially reducing food cravings and portion sizes. These sophisticated mechanisms operate continuously due to Wegovy's once-weekly formulation, providing sustained appetite regulation between doses. The precision engineering required for this extended-release profile contributes to the medication's cost structure whilst delivering consistent therapeutic benefits.
Streamlined Ordering Process for Both Medications
Accessing either Wegovy or Mounjaro through EverydayMeds requires completion of our comprehensive 3-minute online clinical assessment, covering your medical history, current medications, and weight management goals. Following assessment submission, our qualified prescribers review your information within 3 working days (express 24-hour service available), ensuring appropriate medication selection and dosing. Once approved, your chosen medication ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. The ordering system accommodates both medications, allowing you to discuss options with your prescriber before finalising your choice. Payment processing includes automatic application of available discount codes, ensuring you receive the most competitive pricing for your selected treatment.
Storage Advantages: Wegovy vs Mounjaro Practicality
Storage requirements significantly impact the practical cost of Wegovy compared to Mounjaro, particularly for travelling patients. Wegovy maintains stability at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. The FlexTouch pen delivery system requires refrigeration at 2-8°C before first use, with clear temperature indicators to confirm medication viability. This extended room temperature stability reduces waste from temperature excursions and provides greater flexibility for business travel or holidays. Each Wegovy pen contains four doses of medication, with clear dosing windows and automatic needle insertion for consistent delivery. The practical advantages of extended stability may reduce the hidden costs associated with medication replacement due to storage issues.
Cost Per Outcome: Wegovy vs Mounjaro Value Analysis
Evaluating the true cost of Wegovy requires considering cost per percentage of weight loss achieved, though individual outcomes vary significantly based on adherence to diet and exercise requirements. Wegovy's five-dose escalation protocol may reach therapeutic benefit faster than medications requiring more dose adjustments, potentially reducing the time investment before seeing results. The established clinical profile means prescribers have extensive experience optimising Wegovy therapy, potentially reducing trial-and-error periods that increase overall treatment costs.
Long-term cost considerations include the demonstrated weight regain patterns when treatment stops, with patients typically regaining approximately two-thirds of lost weight within one year of discontinuation. This pattern emphasises that weight management represents a long-term commitment, making the ongoing cost of Wegovy part of a sustained health maintenance strategy rather than a short-term intervention. Both Wegovy and Mounjaro are available through EverydayMeds, allowing your prescriber to help you choose the most cost-effective option for your specific circumstances.
Start Your Weight Management Journey Today
The cost of Wegovy represents an investment in clinically-proven weight management technology, with transparent pricing from £79.99 and bundle options for extended treatment periods. Our discount codes FIRST40 and DOSE25 apply automatically at checkout, ensuring you access the most competitive pricing available. EverydayMeds maintains both Wegovy and Mounjaro inventory, allowing direct cost comparison and prescriber guidance on the most suitable option for your budget and clinical needs. Begin with our 3-minute clinical assessment to discuss medication options with qualified healthcare professionals registered with our GPhC #9012878 pharmacy. Visit https://everydaymeds.co.uk/collections/weight-loss to compare both medications and start your supervised weight management programme today.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
